BofA double downgraded Achilles Therapeutics to Underperform from Buy with a price target of 50c, down from $7. The analyst cites the company’s recent program delays and a lack of clear developmental timelines for the double downgrade. The firm thinks continued program delays could be detrimental to Achilles’ future market opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACHL:
